Publications

Publications

Filter Results: (1,248) Arrow Down
Filter Results: (1,248) Arrow Down Arrow Up

Show Results For

Show Results For

← Page 20 of 1,248 Results →
  • 02 Feb 2021
  • Blog Post

Finding My Focus in Health care Amidst a Global Pandemic

decade, legislators have passed countless health care policies that impact how hospitals, insurance companies and pharmaceutical manufacturers deliver services to patients. Even more, the ongoing SARS-CoV-2 pandemic has uncovered major... View Details
  • 16 Jan 2018
  • First Look

First Look at New Research and Ideas, January 16, 2018

https://www.hbs.edu/faculty/Pages/item.aspx?num=53705 Developing Novel Drugs By: Krieger, Joshua, Danielle Li, and Dimitris Papanikolaou Abstract—We analyze firms' decisions to invest in incremental and radical innovation, focusing specifically on View Details
Keywords: Sean Silverthorne
  • April 2019 (Revised January 2025)
  • Case

Clear Link Technologies, LLC: Driving Sales with Peer Effects

By: Christopher Stanton, Richard Saouma and Olivia Hull
The importance of a good peer or coworker is widely discussed, but understanding the glue that makes coworkers valuable is less understood. This case sheds light on the importance of peers and the practices and environments that make a group greater than the sum of its... View Details
Keywords: Talent and Talent Management; Interactive Communication; Experience and Expertise; Decision Making; Training; Design; Compensation and Benefits; Knowledge Acquisition; Knowledge Sharing; Human Capital; Working Conditions; Measurement and Metrics; Outcome or Result; Performance; Performance Improvement; Research; Sales; Salesforce Management; Motivation and Incentives; Telecommunications Industry; Utah; United States
Related
  • March 2012
  • Article

Managing Political Risk in Global Business: Beiersdorf 1914-1990

By: Geoffrey Jones and Christina Lubinski
This article is concerned with business strategies of political risk management during the twentieth century. It focuses especially on Beiersdorf, a pharmaceutical and skin care company in Germany. During World War I, the expropriation of its brands and trademarks... View Details
Keywords: Business Strategy; Government and Politics; Risk Management; Brands and Branding; Problems and Challenges; Communication Technology; Cost; Trademarks; Strategy; Pharmaceutical Industry; Germany
Related
  • October 1996 (Revised December 1997)
  • Case

American Cyanamid (A): Boardroom Response to a Hostile Takeover Offer

American Home Products' (AHP) $9 billion hostile takeover of American Cyanamid (Cyanamid) was the largest mergers and-acquistions transaction in 1994, and made AHP the fourth largest pharmaceutical firm in the United States. At the time of AHP's offer, Cyanamid had... View Details
Keywords: Governing and Advisory Boards; Mergers and Acquisitions; Corporate Governance; Pharmaceutical Industry; United States
Related
  • Web

Faculty & Advisors | MBA

Crinetics Pharmaceuticals (NASDAQ: CRNX), among others. Earlier in her career Dr. Chang was a Project Leader at The Boston Consulting and a member of the Healthcare Practice. Dr. Chang trained clinically in internal medicine and... View Details
  • March 2011 (Revised February 2012)
  • Case

Innovation and Growth at Actelion Ltd.

By: Gary P. Pisano, Daniela Beyersdorfer and Ruth Dittrich
In late 2010, Jean-Paul Clozel, CEO of the Swiss biotech pharmaceuticals firm Actelion, looks back on a successful decade. The small venture that he had started with a few of his scientist colleagues in the late 1990s to discover novel medicine in a research-driven... View Details
Keywords: Business Model; Talent and Talent Management; Innovation and Management; Leadership; Growth and Development Strategy; Product Development; Organizational Culture; Research and Development; Pharmaceutical Industry; Pharmaceutical Industry; Switzerland
Related
  • Web

Curriculum | MBA

could be in a variety of fields related to biotechnology and life sciences including pharmaceutical companies, start-up biotechnology and life science companies, consulting with a focus on biotech/life sciences, policy/ government, or... View Details
  • 11 Sep 2007
  • First Look

First Look: September 11, 2007

Limited was facing significant pricing pressure in their cash cow business, that primarily consisted of manufacturing Active Pharmaceutical Ingredients (APIs). To combat this commoditization, Biocon's leadership had chosen an... View Details
Keywords: Martha Lagace

    Jay W. Lorsch

    Jay W. Lorsch is the Louis Kirstein Professor of Human Relations at the Harvard Business School. He is editor of View Details

    • September 2007
    • Article

    Investigative Negotiation

    By: Deepak Malhotra and Max H. Bazerman
    This article includes a one-page preview that quickly summarizes the key ideas and provides an overview of how the concepts work in practice along with suggestions for further reading. Negotiators often fail to achieve results because they channel too much effort into... View Details
    Keywords: Knowledge Acquisition; Knowledge Use and Leverage; Negotiation Process; Negotiation Tactics; Motivation and Incentives; Perspective; Pharmaceutical Industry
    Related
    • January 2001 (Revised July 2003)
    • Case

    Pharmacyclics: Financing Research & Development

    By: Malcolm P. Baker, Richard S. Ruback and Aldo Sesia
    Pharmacyclics (NASDAQ: PCYC), a pharmaceutical company that manufactures products that will improve existing therapeutic treatments for cancer, arteriosclerosis, and retinal disease, was considering a $60 million private placement in February 2000. The company had more... View Details
    Keywords: Valuation; Cash Flow; Financing and Loans; Business Startups; Financial Strategy; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry
    Related
    • June 2024 (Revised December 2024)
    • Case

    Lana Ghanem: Pushing the Boundaries of Health Care Through Venture Capital

    By: Joshua D. Margolis and Ahmed Dahawy
    Lana Ghanem, managing director of Hikma Ventures, the corporate venture arm of larger pharmaceutical group Hikma, is considering how to grow the venture arm as well as progress her own career. Over the past few years Hikma's executive team had been pressuring the... View Details
    Keywords: Business Divisions; Corporate Entrepreneurship; Investment; Corporate Governance; Health Care and Treatment; Leadership Development; Business or Company Management; Growth and Development Strategy; Business Strategy; Venture Capital; Personal Development and Career; Pharmaceutical Industry; Pharmaceutical Industry; Jordan
    Related
    • January 2014 (Revised December 2014)
    • Case

    GenapSys: Business Models for the Genome

    By: Richard G. Hamermesh, Joseph B. Fuller and Matthew Preble

    GenapSys, a California-based startup, was soon to release a new DNA sequencer that the company's founder, Hesaam Esfandyarpour, believed was truly revolutionary. The sequencer would be substantially less expensive—potentially costing just a few thousand dollars—and... View Details

    Keywords: DNA Sequencing; Life Sciences; Business Model; Innovation ＆ Entrepreneurship; Health Care and Treatment; Genetics; Business Strategy; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; United States
    Related
    • April 2009
    • Case

    GSK's Acquisition of Sirtris: Independence or Integration?

    By: Toby E. Stuart and James Weber
    An executive from pharmaceutical company GSK must choose how much to integrate a recently acquired biotechnology firm, Sirtris. Moncef Slaoui, GSK's global head of R&D, championed the acquisition of Sirtris to gain access to its potentially revolutionary science.... View Details
    Keywords: Mergers and Acquisitions; Resource Allocation; Organizational Change and Adaptation; Organizational Culture; Organizational Structure; Research and Development; Science-Based Business; Integration
    Related
    • 04 May 2017
    • News

    The Error at the Heart of Corporate Leadership

    • October 2019
    • Supplement

    Impax Laboratories: Executing Accretive Transactions (A)

    By: Benjamin C. Esty and Daniel Fisher
    Impax Laboratories was a technology-based pharmaceutical company that used a “dual platform” strategy to sell both generic and branded treatments. While Impax had grown organically for most of its history, it was beginning to use major acquisitions for growth. In the... View Details
    Keywords: Financial Reporting; Financial Statements; Mergers and Acquisitions; Capital Structure; Financial Strategy; Competition; Competitive Advantage; Corporate Strategy; Pharmaceutical Industry; United States
    Related
    • October 2019
    • Case

    Impax Laboratories: Executing Accretive Acquisitions (A)

    By: Benjamin C. Esty and Daniel Fisher
    Impax Laboratories was a technology-based pharmaceutical company that used a “dual platform” strategy to sell both generic and branded treatments. While Impax had grown organically for most of its history, it was beginning to use major acquisitions for growth. In the... View Details
    Keywords: Financial Reporting; Financial Statements; Mergers and Acquisitions; Capital Structure; Competition; Competitive Advantage; Corporate Strategy; Pharmaceutical Industry; United States
    Related

      Henry W. McGee

      Henry McGee joined the HBS faculty in 2013 after retiring as President of HBO Home Entertainment, the digital and DVD program distribution division of Home Box Office, the pioneering premium television company. A member of the Entrepreneurial Management Unit,... View Details

      Keywords: television; motion pictures; media; e-commerce industry; entertainment; broadcasting; distribution; health care; journalism; wholesale; arts; nonprofit industry
      • Research Summary

      Regulatory negotiations and risk communication

      In the pharmaceutical industry a drugs benefits and risks are constantly being weighed by companies, regulators, physicians and drug consumers. While companies and regulators must make decisions based on population statistics about drug outcomes, physicians and drug... View Details